Clinical Trials Browser

Available × OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all

NCT00854841 2009-03-03

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive